Comparative Pharmacology
Head-to-head clinical analysis: IODOTOPE versus MACROTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IODOTOPE versus MACROTEC.
IODOTOPE vs MACROTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodine-131 is taken up by the thyroid gland and emits beta particles and gamma rays, causing destruction of thyroid tissue via radiation-induced cell death.
Not applicable for diagnostic use.
For thyroid ablation: 3.7-5.55 MBq (100-150 μCi) orally as a single dose. For hyperthyroidism: 185-555 MBq (5-15 mCi) orally as a single dose.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
None Documented
None Documented
Terminal half-life is approximately 120-140 days for total body iodine, but the effective half-life for therapeutic use is 8-13 days due to biological turnover in the thyroid. For diagnostic use, effective half-life is 1-2 days.
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Primarily renal: >90% excreted in urine as iodide. Fecal excretion is negligible (<2%).
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical